Showing 1861-1870 of 2652 results for "".
- Laser Vision Correction Market Growth Continues for Third Consecutive Yearhttps://modernod.com/news/laser-vision-correction-market-growth-continues-for-third-consecutive-year/2476315/US laser vision correction procedure volume grew for the third straight year in 2018, reflecting continued strong demand for LASIK and other forms of laser vision correction, according to figures released by The Refra
- EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-yutiq/2476328/EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in
- Statement From FDA Leadership On a Record Year for Device Innovationhttps://modernod.com/news/statement-from-fda-leadership-on-a-record-year-for-device-innovation/2479598/FDA Commissioner Scott Gottlieb, MD, and Jeff Shuren, MD, director for the Center for Devices and Radiological Health, released the following statement addressing a record year for device innovation: “The FDA’s focus on both safety and innovation stems from our historic mission
- EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019https://modernod.com/news/eyepoint-pharmaceuticals-to-launch-dexycu-and-yutiq-in-first-quarter-of-2019/2476226/During a corporate update, EyePoint Pharmaceuticals executives said they expect to launch both Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) in the first quarter of calendar 2019. “EyePoint has made significant progress in
- iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu
- Beaver-Visitec International to Acquire PhysIOL Grouphttps://modernod.com/news/tpg-capital-backs-bvi-to-acquire-physiol-group-sa/2476246/Beaver-Visitec International (BVI) announced it has signed a definitive agreement to acquire PhysIOL Group, a Belgium-based ophthalmic company specializing in the research, development, and manufacture of IOLs, from TA Associates. Financial terms of the transaction were not disclosed.
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- Alcon’s Phaco Development (PD) Program Celebrates 10 Yearshttps://modernod.com/news/alcons-phaco-development-pd-program-celebrates-10-years/2476164/The Phaco Development (PD) program, an initiative between Alcon and specialist training institutes that builds cataract surgical capabilities across Asia and Russia, is celebrating its 10th anniversary this year. Over th
- Report: Laser Vision Correction Procedure Volume Increases for Third Straight Yearhttps://modernod.com/news/report-laser-vision-correction-procedure-volume-increases-for-third-straight-year/2479719/Laser vision correction procedure volume in the United States increased for the third year in a row, indicating a growing demand for LASIK and other laser vision correction procedures, according to data released by the Refractive Surgery Council (RSC). Year-to-date laser vision correction
- EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutuq-24-month-follow-up-data-at-aao/2479724/EyePoint Pharmaceuticals announced the presentation of 24-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Th